Search
Fingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigationalIt was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus. … [A176474] Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis.
Categories: Experimental Unapproved Treatments for COVID-19Tepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalTepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February … In February 2022, tepotinib was approved for use in Europe.[L42200]
ISS-1018
go.drugbank.com/drugs/DB05463InvestigationalIt is also being investigated in combination with rituximab for treatment of b-cell or non-hodgkin's lymphoma. … ISS 1018 is currently being investigated in combination with HBsAg vaccine as a prophylactic treatment for to prevent Hepatitis B in adults.
Glymidine
go.drugbank.com/drugs/DB01382ApprovedIt is used for the concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus. … The mechanism of action of glycodiazine in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral
Categories: Drugs Used in DiabetesBrepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigational[L64097] The FDA approved brepocitinib on August 27, 2026 for the treatment of dermatomyositis in adult patients, making it the first targeted oral therapy approved for the condition.[L64115] … [L64097] Brepocitinib is not recommended in combination with other JAK inhibitors, other TYK2 inhibitors, or biologic DMARDs.
Marnetegragene autotemcel
go.drugbank.com/drugs/DB17595Approved[L56115, L56116] Marnetegragene autotemcel is indicated for pediatric patients with severe LAD-I lacking an available HLA-matched sibling donor.[L56115] … Severe leukocyte adhesion deficiency-I (LAD-I) is a genetic disorder leading to frequent life-threatening infections and high fatality risks among affected pediatric patients.
Synonyms: Autologous CD34+ cells transduced ex vivo with a lentiviral vector (Chim-CD18-WPRE) encoding the ITGB2 geneCorynebacterium diphtheriae
go.drugbank.com/drugs/DB09877ApprovedInvestigationalThe vaccine is intramuscularly administered to provide active immunization against diphtheria in infants and children. … The bacteria culture is grown in a medium and through purification, diphtheria toxin is detoxified with formaldehyde and diafiltered.
Mixtures: PREVENAR 13 SUSPENSION FOR INJECTION, Boostrix Injektionssuspension in einer FertigspritzeGimeracil
go.drugbank.com/drugs/DB09257ApprovedInvestigationalfor continued cancer growth. … Gimeracil's main role within Teysuno is to prevent the breakdown of [DB00544] (5-FU), which helps to maintin high enough concentrations for sustained effect against cancer cells [L933].
Synonyms: Ts-1 (TN)Dermatophagoides farinae
go.drugbank.com/drugs/DB10400ApprovedInvestigationalThis combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for dust mite allergies. … Dermatophagoides farinae extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy.
Products: Standardized Mite, Dermatophagoides farinae, Scratch or Bulk, 30000 AU per mLDermatophagoides pteronyssinus
go.drugbank.com/drugs/DB10401ApprovedInvestigationalThis combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for dust mite allergies. … Dermatophagoides pteronyssinus extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy.
Products: Standardized Mite, Dermatophagoides pteronyssinus, Scratch or Bulk, 30000 AU per mL